Wu Yuanyuan, Sun Xiuzhen, Li Manxiang, Liu Yun, Wang Guizuo, Lu Jiamei
Xi'an Jiaotong University College of Medicine, Xi'an, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2012 Oct;32(10):1431-4.
To identify the immunological characteristics of the recombinant major pollen allergen pTSX2 of Humulus scandens and evaluate its safety in immunotherapy of allergic asthma in mice.
Western blotting was used to characterize the immunological properties of pTSX2, and its immunogenicity in normal mice was evaluated by detecting sIgG and sIgE levels. The mouse models of allergic asthma were immunized with pTSX2 and examined for sIgE and sIgG levels, total cells and eosinophils percentage in BALF, interleukin-4 (IL-4) and interferon-γ (IFN-γ) levels in BALF and spleen homogenate, and changes in lung pathologies.
Western blotting showed that pTSX2 reacted with the majority (about 70%) of sera from patients allergic to Humulus pollen. In normal mice, pTSX2 mainly induced the production of sIgG. In mouse models of allergic asthma, intervention with pTSX2 caused a significant reduction of sIgE and an increase of sIgG (P<0.05), significantly decreased the total cells and eosinophils in BALF (P<0.05), obviously lowered IL-4 but increased IFN-γ in BALF and spleen homogenate (P<0.05), and diminished inflammatory cell infiltration and percentage of eosinophils in the lung tissues.
pTSX2 shows a definite therapeutic effect and safety in the treatment of allergic asthma in mice possibly by inhibiting sIgE and inducing sIgG production, suppressing airway allergic inflammation and regulating the balance between Thl and Th2.
鉴定葎草重组主要花粉过敏原pTSX2的免疫学特性，并评估其在小鼠过敏性哮喘免疫治疗中的安全性。
采用蛋白质免疫印迹法表征pTSX2的免疫学特性，通过检测sIgG和sIgE水平评估其在正常小鼠中的免疫原性。用pTSX2免疫过敏性哮喘小鼠模型，检测其sIgE和sIgG水平、支气管肺泡灌洗液（BALF）中的总细胞和嗜酸性粒细胞百分比、BALF和脾脏匀浆中的白细胞介素-4（IL-4）和干扰素-γ（IFN-γ）水平以及肺部病理变化。
蛋白质免疫印迹法显示，pTSX2与大多数（约70%）对葎草花粉过敏患者的血清发生反应。在正常小鼠中，pTSX2主要诱导sIgG的产生。在过敏性哮喘小鼠模型中，pTSX2干预导致sIgE显著降低，sIgG升高（P<0.05），BALF中的总细胞和嗜酸性粒细胞显著减少（P<0.05），BALF和脾脏匀浆中的IL-4明显降低，但IFN-γ升高（P<0.05），肺组织中的炎性细胞浸润和嗜酸性粒细胞百分比降低。
pTSX2在治疗小鼠过敏性哮喘中显示出明确的治疗效果和安全性，可能是通过抑制sIgE和诱导sIgG产生、抑制气道过敏性炎症以及调节Th1和Th2之间的平衡来实现的。
